Drug Trial Radar · NCT07038876
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
307
Actual
Start
Jun 27, 2025
Primary completion
Jun 4, 2026
Study completion Jun 11, 2026
Sponsor
- Lead sponsor
- MapLight TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.
Conditions
- Schizophrenia
Interventions
PlaceboDrug
Matched Placebo
ML-007C-MA BIDDrug
ML-007C-MA dosed as 210/3 mg BID
ML-007C-MA QDDrug
ML-007C-MA dosed as 330/6 mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment in Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: Baseline and End of Treatment (5 weeks)
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site
Little Rock, Arkansas
Clinical Site
Bellflower, California
Clinical Site
Culver City, California
Clinical Site
Garden Grove, California
Clinical Site
Lemon Grove, California
Clinical Site
Los Angeles, California
Clinical Site
Montclair, California
Clinical Site
Orange, California
Clinical Site
Riverside, California
Clinical Site
San Diego, California
Clinical Site
Sherman Oaks, California
Clinical Site
Torrance, California
Clinical Site
Hollywood, Florida
Clinical Site
Miami Lakes, Florida
Clinical Site
West Palm Beach, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Decatur, Georgia
Clinical Site
Chicago, Illinois
Clinical Site
Marlton, New Jersey
Clinical Site
Staten Island, New York
Clinical Site
North Canton, Ohio
Clinical Site
Austin, Texas
Clinical Site
DeSoto, Texas
Clinical Site
Richardson, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.